StockData
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. (ORMP) stock analysis

ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026Score 12/30
$4.13+0.16 (+4.03%)

Close on Nov 11, 2026Market cap $171.80MP/E 1.0Yield 6.05%

StockData Score

Prices as of Nov 11, 2026How the score works

Value2Growth1Performance1Health5Dividend3

Mixed12 of 30 checks passed

Oramed Pharmaceuticals passes 12 of the 30 checks behind our score; 14 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
2/6
Growth
1/6
Past performance
1/6
Financial health
5/6
Dividend
3/6

What stands out

  • No debt

    Oramed Pharmaceuticals has no borrowings on its latest balance sheet.

  • EPS growing 10%+ a year

    Diluted EPS grew 24.4% a year over the last three fiscal years.

  • Interest well covered

    No meaningful interest expense to cover.

  • Debt covered by cash flow

    There is no debt to cover.

What to watch

  • Return on equity under 15%

    Return on equity was 113% over the last twelve months and averaged -9.3% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -8.4%, below the 10% that usually covers the cost of capital.

  • Revenue growing under 10% a year

    Revenue grew -9.6% a year over the last three fiscal years, short of the 10% we look for.

  • Bankruptcy risk in the grey zone

    The Altman Z-score is 1.96; above 3 is the safe zone and below 1.8 the distress zone.

Valuation2/6

  • P/E below its 5-year median

    Oramed Pharmaceuticals's P/E of 1.0 is below its own 5-year median of 3.7.

  • P/E below the industry

    Oramed Pharmaceuticals's P/E of 1.0 is below the Drugs median of 25.1.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B against the industry

    Needs positive book value.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth1/6

  • Revenue growing under 10% a year

    Revenue grew -9.6% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growing 10%+ a year

    Diluted EPS grew 24.4% a year over the last three fiscal years.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growth against the industry

    Needs revenue for this year and last.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin trend

    This company does not report gross profit.

Past performance1/6

  • Return on equity under 15%

    Return on equity was 113% over the last twelve months and averaged -9.3% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -8.4%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Oramed Pharmaceuticals's return on equity of 113% is above the Drugs median of -58.9%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin against its history

    Needs five years of revenue and net income.

  • Net margin against the industry

    Needs revenue and net income.

Financial health5/6

  • No debt

    Oramed Pharmaceuticals has no borrowings on its latest balance sheet.

  • Debt not rising

    With no debt today, leverage cannot have risen.

  • Debt covered by cash flow

    There is no debt to cover.

  • Interest well covered

    No meaningful interest expense to cover.

  • Short-term assets cover short-term debts

    Current assets are 4.98 times current liabilities.

  • Bankruptcy risk in the grey zone

    The Altman Z-score is 1.96; above 3 is the safe zone and below 1.8 the distress zone.

Dividend3/6

  • Pays a dividend

    Oramed Pharmaceuticals paid dividends worth 6.1% of the share price over the last twelve months.

  • Yield above Treasuries

    The 6.1% yield is above the 4.4% on a 1-year Treasury.

  • Yield in the top quarter

    The top quarter of US dividend payers yield 3.8% or more; Oramed Pharmaceuticals yields 6.1%.

  • Dividend stability

    Fewer than five years of dividend history.

  • Earnings cover

    Needs dividends paid and net income.

  • Cash-flow cover

    Needs dividends paid and free cash flow.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Oramed Pharmaceuticals. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Own 5-year median 3.7
  • Drugs median 25.1

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

High risk

Average value traded per day
$531.21K
Value traded per 1% price move
$390.07K

Downside

Medium risk

Typical loss in a bad month
16.6%
Volatility (annualized)
53%
Sharpe ratio, 1 year
1.44
Beta to the S&P 500 (5Y)
1.44

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2010 to 2025

Gross margin

0.7%−96.0 pts over 5 years

Operating margin

-754.4%−213.1 pts over 5 years

Net margin

3202.5%+3733.6 pts over 5 years

See a number that looks wrong?